InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,954.40
(
-0.17%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
84.00
(
0.54%
)
Bitcoin
57,411.12
(
-1.42%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 222352

Monday, 12/03/2018 7:46:47 AM

Monday, December 03, 2018 7:46:47 AM

Post# of 251670
GSK acquires TSRO for $75/sh cash—a 182% premium relative to TSRO’s closing price on 11/15/18, the day before Bloomberg cited M&A discussions (#msg-144945059):

https://finance.yahoo.com/news/gsk-reaches-agreement-acquire-tesaro-120400498.html

TSRO’s main asset is Zejula (one of three approved PARP inhibitors), which is currently selling at an annualized rate of ~$250M based on a narrow label that will likely be expanded.

The nominal deal value is $5.1B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up